Trial Profile
EValuate Ibrutinib Retention iN Chronic Lymphocytic Leukemia Patients Treated in a rEal World Setting - EVIdeNCE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms EVIdeNCE
- Sponsors Janssen-Cilag
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 30 Dec 2021 Status changed from active, no longer recruiting to completed.
- 27 Nov 2019 Status changed from recruiting to active, no longer recruiting.